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1. Introduction 
Genetic polymorphisms and mutations in drug metabolizing enzymes, transporters, 
receptors, and other drug targets (e.g., toxicity targets) are linked to inter-individual 
differences in the efficacy and toxicity of many medications as well as risk of genetic 
diseases. Validation of clinically important genetic polymorphisms and the development of 
new technologies to rapidly detect clinically important variants are critical issues for 
advancing personalized medicine.  
Pharmacogenomics, which deals with heredity and response to drugs, is the scientific field 
that attempts to explain individual variability of drug responses and to search for the 
genetic basis of such variations or differences (Evans et al., 2001). The inter-individual 
variation in the rate of drug metabolism has been known for many years. Initially, the study 
of pharmacogenetics was only of academic interest, but today it is of major concern to the 
pharmaceutical industry as a means for documenting the metabolism of a new drug in 
development before registration. The knowledge of how a drug is metabolized and which 
enzymes are involved may help to predict drug-drug interactions and the rate at which 
individual patients may metabolize a specific drug. Such information is now required for 
registration by the U.S. Food and Drug Administration (FDA) and similar authorities 
(Salerno & Lesko, 2004a, 2004b). To improve drug safety, the FDA has started to update the 
labels and package inserts of previously approved drugs as new clinical and genetic 
evidence accrues (Frueh et al., 2008; Lesko, 2008).  
The current important step is to incorporate pharmacogenomics data into routine clinical 
practice. As a means of implementing personalized medicine, it is critically important to 
understand the molecular mechanisms underlying inter-individual differences in the drug 
response, namely, pharmacological effect vs. side effect. The occurrence of personal 
variations in the response to a drug may result from many different causes, for example, 
genetic variations and expression levels of drug-targeted molecules, including membrane 
receptors, nuclear receptors, signal transduction components, and enzymes, as well as those 
of drug-metabolizing enzymes and drug transporters (Evans et al., 2001). Recently, tools 
such as next-generation sequencing technologies and genome-wide association studies 
(GWAS) have been used to uncover a number of variants that affect drug toxicity and 
efficacy as well as potential risk of diseases. The costs involved in carrying out GWAS and 
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sequencing have been dropping dramatically, while providing data at an unprecedented 
rate. The GWAS approach has been applied for identifying genetic contributions to 
variations in drug response (The SEARCH Collaborative Group, 2008; Kamatani et al., 2010; 
Cooper et al., 2008; Schuldiner et al., 2009; Ge et al., 2009; Daly et al., 2009). As a result, there 
have been dramatic increases in our understanding of the mechanisms of drug action and of 
the genetic determinants responsible for variable responses to both rarely and widely used 
drugs, such as warfarin, tomoxifen, and clopidogrel. 
Technologies are evolving to transform diagnostic devices for rapid genetic testing. Portable 
devices are being engineered for use in a range of settings to perform robust assays for the 
diagnosis of disease that will improve patient management, and result in greater 
convenience and speed to answer.The genetic diagnostics is a growing field that is gradually 
becoming more user-friendly with the introduction of portable devices and quicker nucleic 
acid detection. Successful genetic diagnostics require 4 major elements, such as rapid 
reaction, low cost, low energy consumption, and simple analysis (with minimal technical 
training and inclusion of controls but no off-instrument processing or reagent preparation). 
In this context, we decided to develop a point-of-care “POC” technology and to apply it to 
medical advances.  
Development of personalized medicine including POC technology requires integration of 
various segments of biotechnology, clinical medicine, and pharmacology. A key 
requirement for advancing personalized medicine is the ability to rapidly and conveniently 
test for patients’ genetic polymorphisms and/or mutations. To address this urgent need, we 
have recently developed a rapid and cost-effective method, named Smart Amplification 
Process (SmartAmp), which enables us to detect genetic polymorphisms or mutations in 
target genes within 30 to 45 minutes under isothermal conditions that do not require DNA 
isolation and PCR amplification (Mitani et al., 2007; Mitani et al., 2009; Ishikawa et al., 2010; 
Aw et al., 2011; Ota et al., 2010; Lezhava et al., 2010; Toyoda et al., 2009; Aomori et al., 2009; 
Watanabe et al., 2007; Okada et al., 2010; Azuma et al., 2011). In this book chapter, we will 
present the technological development and clinical applications of the SmartAmp method. 
2. SmartAmp method 
The SmartAmp method was developed based on the principal concept that DNA 
amplification itself is the signal for detection of a genetic mutation or SNP. Differing from 
the widely-used PCR, the SmartAmp method is an isothermal DNA amplification reaction 
(Mitani et al., 2007; Mitani et al., 2009). In the SmartAmp method, the entire DNA 
amplification process requires five primers: turnback primer (TP), boost primer (BP), folding 
primer (FP), and two outer primers (OP1 and OP2) (Fig. 1). Primers are selected based on 
those algorithms considering the free energy, probability of base-pairing, product size 
range, optimal melting temperature, and product size range. The design of these primers 
contributes to the specificity of SmartAmp. In particular two primers (TP and FP) are 
critically important for the amplification process. The genomic sequence between the 
annealing sites of the TP and FP primers is the target region that will be amplified by the 
SmartAmp reaction. The other primers (BP, OP1, and OP2) are additionally employed to 
accelerate the process and enhance specificity. 
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Fig. 1. Schematic illustration of five primers used for the SmartAmp method: turn-back 
primer (TP), boost primer (BP), folding primer (FP), and two outer primers (OP1 and OP2) 
2.1 Molecular mechanism underlying isothermal DNA amplification 
In isothermal DNA amplification by the SmartAmp method, the initial step of copying a 
target sequence from the genomic DNA is a prerequisite. FP and TP hybridize the template 
genomic DNA. Next, both products primed for the FP and TP are detached from template 
genomic DNA by strand-displacing DNA polymerase, whose extensions are primed by OP1 
and OP2. Single-stranded DNA products, thus displaced, become templates in the second 
step for the opposing FP and TP. These single stranded DNA products are generated by the 
strand-displacement activity of the DNA polymerase, being primed from the flanking 
region of OP primers adjacent to the target sequence. The resulting DNA products are 
referred to as “intermediate products”, IM1 and IM2, which play key roles in the subsequent 
amplification steps (Fig. 2).  
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Fig. 2. Formation of intermediate products in the initial step of the SmartAmp reaction. The 
priming events of the SmartAmp reaction generate two intermediates (i.e., IM1 and IM2). 
The formation of those intermediate products (IM1 ad IM2) is the rate-limiting step in 
SmartAmp-based isothermal DNA amplification. IM1 has the TP sequence at the 5’ end and 
the FP complementary sequence at the 3’ end; and IM2 is complementary to IM1 (Fig. 3). 
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The initial self-priming site on IM1 is the 3’-end of the FP sequence of IM1. Concatenated 
products of IM1 are synthesized by an elongation process termed pathway A. The 
characteristic feature of the products of pathway A is that the free 5’ and 3’ ends carry TP 
and its complementary sequence, forming long double stranded hairpin DNA. The initial 
self-priming elongation site on IM2 is located at the 3’ end of the TP sequence of IM2. Long 
concatenated DNA products are synthesized as in pathway A, but end products in pathway 
B are different. The long-hairpin DNA products of pathway B carry FP and its 
complementary sequence at the free 5’ and 3’ ends respectively. There is another elongation 
pathway which starts from the 3’ end of a free TP-primer that hybridizes to the looping 
structure of the TP complementary sequence, which is located at the intermediate region of 
the long products of pathway A. Thus, concatenated DNA products are formed in the 
SmartAmp reaction. The resulting DNA products could be detected by conventional agarose 
gel electrophoresis, where DNA ladder patterns represented the formation of concatenated 
DNA products (Mitani et al., 2007) (Fig. 3).  
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Fig. 3. The molecular mechanism underlying isothermal DNA amplification. Formation of 
concatenated DNA products in the SmartAmp reaction. Self-priming DNA synthesis from 
each of the intermediates, IM1 and IM2, creates hairpin molecules via pathway A or B. 
These structures lead to further self-primed DNA synthesis to create dimeric amplicons and 
then subsequently concatenated DNA products. 
2.2 Molecular mechanism underlying SNP detection 
To ensure the high fidelity of SNP detection by the SmartAmp method, exponential 
amplification of mis-primed DNA must be suppressed. In the original SmartAmp method, 
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this was achieved by adding either the mismatch binding protein (MutS) Thermus aquaticus 
(Mitani et al., 2009) or a competitive probe (Toyoda et al., 2009) to the reaction mixture. 
MutS inhibits background DNA from entering the amplification cycle by specifically 
binding to mis-primed amplification products (Fig. 4). In addition, a combination of the 
asymmetrical primers, i.e., TP and FP is used to minimize alternative mis-amplification 
pathways (Mitani et al., 2007).  
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Fig. 4. The mechanism of allele discrimination as exercised by Taq MutS. SNP typing with a 
wild-type allele detection primer, using the wild-type allele (left) and the mutant-type allele 
(right) as templates. The wild-type allele detection primer is designed to encompass the SNP 
nucleotide site at each 3’-position. Amplification is not allowed when the primer 
mismatches with the mutant-type allele (Check 1). If check 1 fails, Taq MutS strongly binds 
to mismatched nucleotides and Aac DNA polymerase can not strand-displace or extend the 
newly synthesized strand (Check 2). 
The SmartAmp method utilizes Aac polymerase as a DNA polymerase with strand-
displacement activity. This DNA polymerase is highly resistant to cellular contaminants and 
hence works directly on blood samples, just after a simple heat treatment (98ºC, 3 min) to 
degrade RNA and denature proteins. This is a great advantage of the SmartAmp method 
over the commonly used PCR-based techniques that require careful DNA extraction. In the 
conventional method, the enzymatic activity of Taq DNA polymerase is easily inhibited by 
impurities. 
2.3 Example of SNP detection by SmartAmp method 
Clinical application of SmartAmp to practical SNP detection should be evaluated with 
clinical samples (either blood or genomic DNA) according to the principle of amplification 
versus non-amplification as compared to threshold values. The amount of DNA-
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intercalating SYBR Green I dye during the reaction can be monitored in a real-time PCR 
system (e.g., Mx3000P), and thereby SNP typing can be determined by referring to the 
intensity of fluorescence. 
Each SmartAmp2 reaction is performed in a 25 μl-volume tube at 60˚C. The standard 
reaction mixture contains 3.2 μM each of TP and FP, 0.4 μM each of OP1 and OP2, 1.6 μM 
BP, 1.4 mM dNTPs, 5% dimethyl sulfoxide (DMSO), 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 
10 mM (NH4)2SO4, 8 mM MgSO4, 0.1% Tween 20, SYBR Green I (1/100,000-diluted), 40 units 
of Aac DNA polymerase, 1.5-2.4 μg of Taq MutS (optional) and 1 μl of blood or genomic 
DNA sample. Each reaction mixture should be incubated at 60˚C for 40 - 60 minutes under 
isothermal conditions in a real-time PCR model Mx3000P system (Stratagene, La Jolla, CA, 
USA) where changes in the fluorescence intensity of SYBR Green I dye is monitored to 
detect the DNA amplification. Fig. 5 presents the results of the SmartAmp method when 
applied to detection of a clinically important SNP 460G>A in exon 7 of the human 
thiopurine S-methyltransferase (TPMT) gene. Clinical importance of this SNP will be 
discussed in the following section. 
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Fig. 5. Schematic illustration of the human TPMT gene and detection of the SNP 460G>A by 
the SmartAmp method. Two panels depict the time-courses of the SmartAmp assay 
reactions with TPMT–specific primers carrying WT (460G) or SNP (460A) alleles; namely, 
G/G homozygote and A/A homozygote.  
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3. Clinical applications of SmartAmp method 
Hitherto, we have proven that the SmartAmp method is capable of detecting SNPs in drug 
transporter genes (e.g., ABCB1, ABCG2, and ABCC11) (Ishikawa et al., 2010; Aw et al., 2011; 
Ota et al., 2010; Toyoda et al., 2009) as well as in drug metabolizing enzyme genes, including 
those of cytochrome P450s, vitamin K epoxide reductase (VKORC1), and UDP-
glucuronosyltransferase UGT1A1 (Aomori et al., 2009; Watanabe et al., 2007). Here we 
present other examples of SNP detection by the SmartAmp method, namely detection of 
genetic polymorphisms in human TPMT and ABCC4 genes to predict thiopurine-induced 
adverse reactions in certain sub-populations of patients.  
3.1 Thioprine toxicity and genetic polymorphisms in TPMT gene 
Thiopurines are effective immunosuppressants and anticancer agents used for treating 
childhood acute lymphoblastic leukemia, acute myeloblastic leukemia, autoimmune disease, 
rheumatoid arthritis, and inflammatory bowel diseases. The intracellular accumulation of 
such active metabolites as 6-thioguanine nucleotides (6-TGN), however, causes dose-
limiting hematopoietic toxicity (Weinshilboum & Sladek, 1980). TPMT deficiency has been 
reported to exacerbate thiopurine toxicity (Fig. 6).  
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TPMT TPMT
XO IMPDH
ABCC4
HGRPT
Non-
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AZAAZA
6-TGN Toxicity
ATP ADP
 
Fig. 6. Cellular metabolism of azathioprine (AZA) and transport. HGRPT, hypoxanthine-
guanine phosphoribosyl transferase; IMPDH, inosine monophosphate dehydrogenase; XO, 
xanthine oxidase. 6-MMP, 6-methylmercaptopurine; 6-MMPR, 6-methylmercaptopurine 
ribonucleosides; 6-MP, 6-mercaptopurine; 6-TGN, 6-thioguanine nucleotide; 6-TIMP, 6-
thiosine 5’-monophosphate; 6-TU; 6-thiouric acid; 6-TXMP, 6-thioxanthosine 
monophosphate; GMPS, guanosine monophosphate synthetase; 6-TGN, 6-thioguanine 
nucleotides. AZA is non-enzymatically converted to 6-MP in the cell. HGRPT is responsible 
for conversion of 6-MP to 6-TIMP. Thiopurine toxicity is caused by cellular accumulation of 
6-TGN. Human ABC transporter ABCC4 plays a role of extruding the cytotoxic 6-TGN from 
the cells. 
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The enzyme TPMT operates in the main inactivation pathway for thiopurine drugs. The 
TPMT gene comprising 10 exons is located on chromosome 6p22.3 (Fig. 7). TPMT activity 
has been proven by numerous studies to be inversely correlated to 6-TGN levels in 
erythrocytes and other hematopoietic tissues (Krynetski et al., 1995; Evans, 2004; Anstey et 
al., 1992; Stolk et al., 1998; Yates et al., 1997; Black et al., 1998; Clunie et al., 2004). 
Polymorphisms in the TPMT gene can lead to intermediate, low, or no TPMT activity in 
certain patients, who are thus at an increased risk of developing thiopurine-induced life-
threatening hematologic toxicity. Therefore, the thiopurine dose should be reduced by 50% 
for intermediate and by 80 to 90% for poor metabolizers to reduce the toxicity risk. There are 
a total of 24 functionally related alleles that have been reported to date, i.e., TPMT*1 to *18 
and *20 to *23 (Schütz et al., 2000; Schaeffeler et al., 2008; Lee et al., 2008). TPMT*1 is the 
wild-type allele with high enzymatic activity. The TPMT*2 allele has one non-synonymous 
SNP of 238G>C (Ala80Pro). The TPMT*3A allele carries two non-synonymous SNPs of both 
460G>A (Ala154Thr) and 719A>G (Tyr240Lys), while the TPMT*3B and TPMT*3C alleles 
each carry one non-synonymous SNP of 460G>A (Ala154Thr) and 719A>G (Tyr240Lys), 
respectively. While TPMT*2 is the first variant allele described, this allele is much less 
common than TPMT*3A. Population studies have shown that approximately 10% of 
Caucasians and African Americans inherit one non-functional TPMT*3A allele. This non-
functional allele is not commonly seen in Asians. In Korean populations, TPMT*3C (0.88-
2.54%) and *6 (0.25-1.27%) were found to some extents (Schaeffeler et al., 2008; Lee et al., 
2008). Tai et al. reported that enhanced degradation of TPMT allozymes encoded by the 
TPMT*2 and TPMT*3 alleles is the mechanism for the decreased levels of TPMT protein and 
enzyme activity inherited as a result of these alleles (Tai et al., 1997). Subsequently, Wang et 
al. have demonstrated that the rapid degradation of TPMT*3A involves molecular 
chaperones, such as the heat shock proteins hsp70 and hsp90, and that TPMT*3A can also 
form intracellular aggresomes (Wang et al., 2003; Wang et al., 2005; Wang & Weinshilboum, 
2006). 
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Fig. 7. The genomic organization of the human TPMT gene and five different alleles, i.e., 
TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, and TPMT*6. Non-synonymous SNPs of 238G>C 
(Ala80Pro), 460G>A (Ala154Thr), 539A>T (tyr180Phe), and 719A>G (tyr240Cys) are 
indicated by arrows. 
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3.2 SNP 2269G>A (Glu757Lys) in ABCC4 gene and thiopurine toxicity 
For largely unknown reasons, there are subsets of Japanese patients who suffer from dose-
limiting hematopoietic toxicity, but are not TPMT deficient (Takatsu et al., 2009). Recent 
studies have revealed that ABCC4 protects against thiopurine-induced hematopoietic 
toxicity by actively exporting thiopurine nucleotides (Krishnamurthy et al., 2008; Ban et al., 
2010). ABCC4 is reportedly involved in the transport of antiviral agents, such as 
azidothymidine, adefovir, tenofovir, lamivudine, and ganciclovir (Shuetz et al., 1999; Adachi 
et al., 2002; Anderson et al., 2006; Imaoka et al., 2007), as well as anticancer drugs including 
6-MP, 6-TG, methotrexate, and the camptothecins (Lee at al., 2000; Chen et al., 2002; 
Wielinga et al., 2002; Tian et al., 2005). 
ABCC4 is a highly polymorphic gene with more than 20 missense genetic variants identified 
in the National Centre for Biotechnology Information (NCBI) database and the 
Pharmacogenetics Research Network (PGRN). Despite this situation, few data are available 
regarding the functions of these variants. Krishnamurthy et al. have recently shown that 
patients carrying SNP 2269G>A (Glu757Lys) in the human ABCC4 gene have severely 
reduced ABCC4 function resulting from an impairment of its cell membrane localization 
(Krishnamurthy et al., 2008). ABCC4 protects against thiopurine-induced hematologic 
toxicity by actively exporting 6-TGN, a toxic metabolite in the thiopurine drug metabolic 
pathway. Interestingly, the ABCC4 2269G>A SNP is common in the Japanese population (15 
to 18% frequency), which suggests that this non-synonymous SNP could provide an 
explanation for the unsolved thiopurine toxicity that is not associated with genetic 
polymorphisms of TPMT (Takatsu et al., 2009; Ban et al., 2010; Ando et al., 2001). 
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Fig. 8. Schematic illustration of the human ABCC4 gene located on chromosome 13q32.1. 
The SNP 2269G>A that resides in exon 18 was detected by the SmartAmp method. 
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Unlike the situation for TPMT, the effects of the 2269G>A polymorphism in the ABCC4 gene 
have been relatively unexplored. Most recently, Ban et al. have investigated an association 
between the 2269G>A polymorphism in the ABCC4 gene and thiopurine sensitivity in 
Japanese patients with inflammatory bowel disease (IBD) (Ban et al., 2010). A total of 235 
samples from IBD patients were analyzed in their clinical study. They showed that the 6-
TGN levels in red blood cells were significantly higher in patients with the allele of ABCC4 
SNP 2269G>A than in patients with the wild-type allele (P = 0.049). The white blood cell 
count was significantly lower in patients with the SNP 2269G>A allele than in patients with 
the wild-type allele. Among 15 patients with leucopenia (< 3 x 109/l), seven carried the SNP 
2269G>A allele (Ban et al., 2010). The odds ratio of carrying the SNP allele and having 
leucopenia was 3.33 (95% confidence interval 1.03-10.57, P = 0.036) (Ban et al., 2010). As 
compared with the azathiopurine (AZA) dose of 2 to 3 mg/kg recommended in Western 
countries (Lichtenstein et al., 2006), lower doses of AZA (0.6 to 1.2 mg/kg) are used in Japan 
because of the relatively higher sensitivity to AZA (Hibi et al., 2003). Those results strongly 
suggest that the ABCC4 SNP 2269G>A is a new diagnostic marker indicative of thioprine 
toxicity/sensitivity in Japanese patients with IBD. In this context, the SmartAmp method for 
rapid detection of the ABCC4 SNP 2269G>A (Fig. 8) provides a practical tool for prediction 
of thioprine toxicity/sensitivity in Japanese patients with IBD. 
4. Conclusion 
Accumulating evidence strongly suggests that genetic polymorphisms in drug metabolizing 
enzymes, transporters, receptors, and other drug targets (e.g., toxicity targets) are linked to 
inter-individual differences in the efficacy and toxicity of many medications. The genetic 
polymorphisms of drug metabolizing enzymes and transporters have been studied in many 
laboratories worldwide. In fact, efforts to discover and characterize gene polymorphisms 
resulted in new diagnostic tests for discriminating between different gene alleles and better 
strategies for pharmacotherapy.  
To realize the promise of individualized medicine, however, genetic diagnosis should be 
further integrated with therapy for selecting drugs and treatments as well as for monitoring 
results. It is also critically important to reduce the cost of genetic diagnosis. Technologies are 
evolving to transform diagnostic devices for rapid genetic testing. Portable devices are being 
engineered for use in a range of settings to perform robust assays for the diagnosis of 
disease that will improve patient management, and result in greater convenience and speed 
to answer. Indeed, the POC diagnostics is a growing field that is gradually becoming more 
user-friendly with the introduction of portable devices and quicker nucleic acid detection.  
The isothermal amplification technologies have a potential to cover different applications. A 
key requirement for the advancing personalized medicine resides in the ability of rapidly 
and conveniently testing patients’ genetic polymorphisms and/or mutations. With this 
respect, isothermal nucleic acid amplification technologies, including the SmartAmp 
method, are expected to translate into less complex and less expensive instrumentation.  
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